From Aiolos to Kailera: Who Captures the Value in a China-to-Global NewCo?

Written By Yihang Chen
Yihang Chen
Previous

BINSA and the WuXi AppTec Case: Two Distinct Tracks in U.S. Biotech National Security Policy
Next

Clinical Going Global: Why Australia and Europe Matter More for Chinese Biotech